Hansoh Pharma: EQRx's marketing authorization application for aumolertinib for the treatment of NSCLC with epidermal growth factor mutations was accepted by the EMA
On December 2, 2022, Hansoh Pharma (03692.HK), a Hong Kong-listed company, announced that the European Medicines Agency ("EMA") had accepted the marke...
Read more